NEW YORK (GenomeWeb News) – Roche today reported that its sales for its molecular diagnostics products fell 3 percent for the first quarter as revenues for its Diagnostics Division overall grew 1 percent.

The Swiss diagnostics, pharmaceuticals, and research products firm reported total group sales of CHF 11.59 billion ($12.45 billion), up 5 percent year over year, and driven by its pharmaceutical products sales, which rose 6 percent to CHF 9.17 billion from CHF 8.62 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: The sea anemone is sequenced, a team describes a CRISPR/Cas9-based approach to label specific sites in the genome, and more. 

In a short video, CNN introduces viewers to a fecal transplant poop donor and explains how the treatments are made.

Researchers are testing the use of transgenically altered diamondback moths as an alternative to pesticides in controlling the bugs.

Two recent papers published in Science and Nature Medicine describe work that may result in a universal vaccine for the flu.